Germany
Japan
United Kingdom
China
Dystonin (DST) human monoclonal antibody, clone H5E.Hy.4B
| Applications | IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Primary Antibodies
View as table DownloadDystonin (DST) human monoclonal antibody, clone H10D-Hy-8B
| Applications | IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
SARS-CoV-2 monoclonal antibody (CB6 biosimilar)
| Applications | ELISA, FC |
| Reactivities | SARS-CoV-2 |
| Conjugation | Unconjugated |
SARS-CoV monoclonal antibody (CR3022 biosimilar)
| Applications | ELISA, FC |
| Reactivities | SARS-CoV-2 |
| Conjugation | Unconjugated |
Recombinant Anti-Fluorescein (Clone 4-4-20 (enhanced))
| Conjugation | Unconjugated |
| Modifications | This is a chimeric human antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Fluorescein (Clone 4-4-20 (enhanced))
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-Fluorescein (Clone 4-4-20 (enhanced))
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-Fluorescein (Clone 4-4-20 (enhanced))
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-erbB-2 (Her-2/neu) (Clone 4D5-8 (trastuzumab))
| Applications | ELISA, FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-hapten 4-hydroxy-3-nitrophenyl acetyl (NP) (Clone B1-8)
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-hapten 4-hydroxy-3-nitrophenyl acetyl (NP) (Clone B1-8)
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-hapten 4-hydroxy-3-nitrophenyl acetyl (NP) (Clone B1-8)
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-hapten 4-hydroxy-3-nitrophenyl acetyl (NP) (Clone B1-8)
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-CD20 (Clone 10F381 (rituximab))
| Applications | FC |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-Beta-galactosidase (Clone 13R4)
| Applications | FC, WB |
| Reactivities | Escherichia coli |
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-Beta-galactosidase (Clone 13R4)
| Applications | FC, WB |
| Reactivities | Escherichia coli |
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-Beta-galactosidase (Clone 13R4)
| Applications | FC, WB |
| Reactivities | Escherichia coli |
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-Beta-galactosidase (Clone 13R4)
| Applications | FC, WB |
| Reactivities | Escherichia coli |
| Conjugation | Unconjugated |
| Modifications | This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. |
Recombinant Anti-TNF alpha (Clone cA2 (Infliximab))
| Applications | ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TRP-1, gp75 (Clone TA99)
| Applications | ELISA, FC, IF, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
USD 523.00
2 Weeks
Recombinant Anti-IL-2R alpha (CD25) (Clone Basiliximab)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD41 (Clone 7E3 (Abciximab))
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD33 (Clone hP67.6 (Gemtuzumab))
| Applications | FC, IF |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-Human Ephrin Type A receptor 2 (Clone 1C1)
| Applications | ELISA, FC, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-CD40L (Clone hu5c8 (Ruplizumab))
| Applications | FC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
USD 523.00
2 Weeks
USD 523.00
2 Weeks
Recombinant Anti-alpha 5 beta 1 Integrin (Clone M200 (Volociximab))
| Applications | ELISA, FC, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD4 (Clone CE9.1 (Clenoliximab))
| Applications | ELISA, FC, IHC |
| Reactivities | Chimpanzee, Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-alpha-gal epitope (Clone m86)
| Applications | ELISA, FC |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD11a (Clone hu1124 (Efalizumab))
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-OX40L (Clone R4930 (Oxelumab))
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-ED-B domain of fibronectin (Clone A2)
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-ED-B domain of fibronectin (Clone G4)
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Bet v 1 (Clone M0418)
| Applications | ELISA |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Phl p 1 (Clone Clone 25)
| Applications | ELISA, WB |
| Reactivities | Rat |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-VEGF (Clone Bevacizumab)
| Applications | ELISA, FC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
USD 523.00
2 Weeks
Recombinant Anti-Integrin alpha 4 (Clone Natalizumab)
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-TNF alpha (Clone D2E7 (Adalimumab))
| Applications | ELISA, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Active filters
Antibody Hosts
- Human
Conjugates
- Unconjugated
Filter by
Category
Target Symbol
- S (15)
- CD274 (7)
- N (6)
- EGFR (4)
- FITC (4)
- GLB1 (4)
- TNF (3)
- CD80 (2)
- FN1 (2)
- IL2RA (2)
- S PROTEIN (2)
- ALPHA-GAL EPITOPE (1)
- BETVI (1)
- CD22 (1)
- CD33 (1)
- CD38 (1)
- CD4 (1)
- CD40 (1)
- CD40LG (1)
- CD52 (1)
- CD70 (1)
- CEA (1)
- DESMOSOME/HEMIDESMOSOME (1)
- EPHA2 (1)
- ERBB2 (1)
- F (1)
- FAS (1)
- FCGR1A (1)
- GM2 (1)
- IL6R (1)
- ITGA2B (1)
- ITGA4 (1)
- ITGA5 (1)
- ITGAL (1)
- MS4A1 (1)
- PHLPI (1)
- RHD (1)
- TNFSF4 (1)
- TYRP1 (1)
- VEGFA (1)
Reactivities
Applications
Isotypes
Clonalities
Modifications
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (13)
- This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (12)
- This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (11)
- This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric human antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)